InMode

Co-founder and CTO Michael Kreindel leads the technology roadmap, drawing on decades of physics and engineering expertise in RF and laser-based energy systems. Both Kreindel and CEO Moshe Mizrahy remain actively involved in product design, a continuity that dates back to their prior venture, Syneron Medical. The clinical advisory function is supported by InMode's network of practicing surgeons and dermatologists who provide feedback on procedural protocols and device ergonomics.

By owning the manufacturing process in Israel and employing a direct sales force rather than third-party distributors, InMode captures margin that would otherwise go to intermediaries. This structure typically sustains gross margins above 80% and has delivered net margins near 40% annually since fiscal 2021. The trade-off is higher fixed operating costs, as the company carries the salaries and training expenses of its own representatives.

Co-founders Moshe Mizrahy and Michael Kreindel previously built Syneron Medical, a pioneer in combined optical and RF aesthetic devices that went public on Nasdaq in 2004 and later merged with Candela. InMode's genesis in 2008 reflected a deliberate departure toward RFAL (Radio-Frequency Assisted Lipolysis) — a technology the founders felt was underserved by Syneron's product line. There is no ongoing corporate relationship between the entities.

The United States accounts for the majority of InMode's sales, reflecting the country's high concentration of plastic surgeons, dermatologists, and medical spas. Canada, India, and Western European markets form the next tier. The company reports segment revenue across the Americas, EMEA, and Asia-Pacific, with direct-sales operations in each region supported by local training centers and clinical specialists.

InMode has historically avoided acquisitions, preferring to develop devices internally through its R&D team in Israel. With over $700 million in cash and equivalents reported as of early 2024, the company has expanded its capital-return program; the board authorized a $100 million share repurchase program in February 2024. Dividends have not been part of the capital-allocation policy to date.

Investors have questioned whether the rise of GLP-1 agonists like semaglutide could reduce demand for body-contouring procedures. InMode management has acknowledged that rapid weight loss may shift patient interest toward skin-tightening and fat-redistribution treatments — categories where its RFAL and fractional RF platforms compete — but has not quantified any material change in purchasing patterns as of early 2024.

InMode owns its full manufacturing process in Yokneam Illit, Israel, and retains in-house the core patents covering bipolar RF delivery, temperature monitoring, and specific handpiece designs. The majority of competitors in the aesthetic-device space contract manufacturing to third parties or license key technologies from university labs. InMode's IP posture allows it to launch iterative upgrades — such as the Morpheus8 Burst handpiece — on shorter timelines than typical MedTech cycles.